Cancer Moonshot Update; Olaparib for Ovarian Cancer - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     The Cancer Moonshot: Moving from Planning to Research 11/19/2018 Dr. Dinah Singer, co-chair of the Cancer Moonshot Blue Ribbon Panel, provides an update to the cancer community on the science being supported under the Moonshot initiative. Olaparib after Initial Treatment Delays Ovarian Cancer Progression 11/20/2018 In a recent trial, the PARP inhibitor olaparib substantially delayed ovarian cancer from coming back after the first line of chemotherapy. Could the findings change the standard of care for newly diagnosed ovarian cancer with a BRCA mutation?

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892